Science AI Journal
Medicine · Research topic

Open research questions in Neurofibromatosis and Schwannoma Cases

271 gap statements mined from Neurofibromatosis and Schwannoma Cases papers in our 7.9M-paper local library, which holds 1,105 papers on the topic — drawn mostly from each paper's own stated research gap, future-work, challenge and limitation notes, and its abstract. The ones listed below are a selection still marked open; each names the study that raised it, with a DOI link where the paper has one.

Choosing where to publish on Neurofibromatosis and Schwannoma Cases? See the ranked Medicine journals.

What the literature leaves open

  • Second, the sample size (n = 64, with 10 secondary stabilization events) is insufficient to support robust multivariable inference.

    Contralateral vs. ipsilateral hemilaminectomy for spinal meningiomas: impact on resection completeness, stability, and recurrence · 2026 · DOI

  • The analysis further lacks data on late toxicities, recurrence patterns, and patient-reported quality of life.

    Comparative outcomes of proton and photon therapy in the management of malignant peripheral nerve sheath tumors · 2026 · DOI

  • Although the downstream mechanisms remain to be defined, our findings extend the consequences associated with NF1 loss beyond proliferative signaling to include altered responses to vacuolizing stress.

    Curcumin-Induced Vacuolizing Stress Reveals a Vulnerability Associated with NF1 Loss in Schwann Cells · 2026 · DOI

  • The recently approved MEK-inhibition therapy targeting the RAS pathway, including selumetinib and mirdametinib, has revolutionized the traditional surgical management of NF1, although it is limited to pNF patients and is not curative, but it can stabilize tumor progression. More therapeutic methods are called for other NF1 manifestations, especially for the prevention, control, and cure of malignant NF1 tumors.

    Neurofibromatosis Type 1: Genetic Mechanisms and Advances in Therapeutic Innovation · 2025 · DOI

  • Despite advances from genomic studies in identifying key events driving neurofibroma progression, major challenges remain in predicting malignant transformation potential. The rarity and heterogeneity of MPNST hinder biomarker validation and limit the power of therapeutic trials.

    The Pathogenesis of the Neurofibroma-to-Sarcoma Transition in Neurofibromatosis Type I: From Molecular Profiles to Diagnostic Applications · 2025 · DOI

  • These gaps, within a clinical landscape reshaped by the approval of novel targeted therapies, warrant further investigation and should be prioritized in future research efforts.

    Management of plexiform neurofibromas in neurofibromatosis type 1: An Italian Delphi consensus · 2026 · DOI

  • Although our analyses reviewed retrospective data in an exploratory manner, the findings we identified are statistically robust and should be seen as hypothesis-generating associations that warrant further investigation.

    Human leucocyte antigen class I and II alleles are associated with tumor susceptibility in neurofibromatosis type 1 · 2026 · DOI

  • Due to the retrospective design, details regarding EEG and were lacking for some patients.

    Epilepsy in paediatric neurofibromatosis type 1: clinical features and associated factors in a single-centere cohort · 2026 · DOI

  • We show that DNA hypomethylation alone is insufficient to kill MPNST cells, regardless of PRC2 status.

    DNA Hypomethylation Is Not Cell Intrinsically Toxic to Polycomb Repressive Complex 2 Deficient Malignant Peripheral Nerve Sheath Tumors · 2026 · DOI

  • MITF-rearranged PEComas are rare, and their relationship to MITF-altered melanocytic tumors remains incompletely characterized.

    Malignant MITF ‐Rearranged PEComa With Novel EEF1A1::MITF Fusion · 2026 · DOI

  • The composition of a compact score varied with platform and preprocessing, so no fixed single-sample classifier is warranted.

    A Reproducible Transcriptomic Program of Neurofibroma‐to‐Malignant Peripheral Nerve Sheath Tumor Transformation · 2026 · DOI

  • Prospective studies incorporating molecular stratification and adaptive radiotherapy are warranted.

    Stereotactic radiosurgery for NF2-related schwannomatosis and schwannomatosis-associated spinal tumors: a single-institution cohort · 2026 · DOI

  • Conus medullaris syndrome (CMS), a rare and frequently underrecognized cause of chronic LBP, illustrates the consequences of delayed diagnosis and underscores the need for systemic improvements in early detection.

    Conus medullaris tumor co-existed with chronic low back pain: a case report and literature review · 2025 · DOI

  • To our knowledge, a case of bilateral cervical ganglioneuroma with myelopathic symptoms in a patient aged 80 years has not been previously reported in the literature.

    Resection of bilateral dumbbell C2 ganglioneuroma · 2025 · DOI

  • The underlying cause of bone impairment in these patients remains poorly understood, especially in children.

    Neurofibromatosis type I (NF1) and bone involvement in a pediatric setting: insights from FGF23 levels · 2025 · DOI

  • Ongoing monitoring is crucial, and additional research on MEK inhibitors and genetic profiling is imperative for tailoring treatment strategies.

    Malignant peripheral nerve sheath tumor in early childhood: a case report of a diagnostic challenge · 2025 · DOI

  • Regarding our case, the presence of widespread recent and previous thrombi in the placenta remains to be clarified.

    Nerve Sheath Myxoma in Pregnancy: A Case Report · 2024 · DOI

  • Despite NF1 being one of the most common autosomal dominant genetic disorders, data from adult individuals in several world regions remain elusive, including Hispanics.

    Case report: Benign and malignant tumors in adult patients with neurofibromatosis type 1: a comprehensive case series from a large oncologic reference center · 2024 · DOI

  • The use of radiotherapy in patients with neurofibromatosis type 1 is limited due to the risk of radiation-induced tumors. The sample size of this study is small, with only two cases reported.

    Radiotherapy for low grade gliomas in children with neurofibromatosis type 1: when there is no other choice. Case Report · 2026 · DOI

  • In this setting, tracer avidity and bone erosion alone are insufficient to infer malignancy; instead, integrated interpretation of MRI/CT morphology, metabolic imaging for extent mapping and staging, and clinicoradiologic context is essential.

    Case Report: Giant L1 dumbbell-shaped spinal schwannoma with osteolytic destruction and intense [18F]FDG uptake on PET/CT mimicking a malignant tumor · 2026 · DOI

  • The use of AI in rare diseases is associated with challenges such as standardizing small patient groups. The necessity of interdisciplinary collaboration between experts in genetics, bioinformatics, laboratory medicine, and clinical medicine. The lack of detailed information about the AI4NEF platform, including its architecture, validation process, and clinical implementation.

    Artificial intelligence in neurofibromatosis type I: diagnostic and therapeutic opportunities · 2026 · DOI

  • The study aims to address this gap by investigating the common molecular links in the tumorigenesis of NF1 and NF2.

    Loss of EPB41L3: a common molecular link in the tumorigenesis of neurofibromatosis types 1 and 2 · 2026 · DOI

  • The PNST microenvironment is shaped by dynamic interactions between Nf1-/- SCs and Nf1+/- immune cells, which modulate both the initiation and progression of NF1- associated tumors.

    The NF1+/- Immune Microenvironment: Dueling Roles in Neurofibroma Development and Malignant Transformation · 2024 · DOI

  • Stay well-updated with the current WHO classification of peripheral nerve sheath tumors. Knowledge of genetic syndromes associated with these tumors (NF1, NF2, schwannomatosis) aids diagnosis. Recommend genetic counselling for patients with multiple tumors or younger patients with solitary tumors.

    Imaging of Peripheral Intraneural Tumors: A Comprehensive Review for Radiologists · 2025 · DOI

  • The development of more advanced AI models to support therapeutic decision-making in NF1. The integration of AI with other technologies, such as genomic analysis, to improve diagnosis and treatment. The evaluation of the effectiveness of AI-based platforms, such as AI4NEF, in clinical settings.

    Artificial intelligence in neurofibromatosis type I: diagnostic and therapeutic opportunities · 2026 · DOI

Most-cited papers in Neurofibromatosis and Schwannoma Cases

Most recent work

Find a gap in your own Neurofibromatosis and Schwannoma Cases sub-topic

This page shows what the Neurofibromatosis and Schwannoma Cases literature already flags as unresolved. To narrow it to your specific question, search the Research Gap Finder: the search is free with a free account and lists the papers closest to your topic first. Unlocking that topic (50 credits, charged once) fills the comparison table from our 7.9M-paper local library and writes the gaps from its rows.

Open the Research Gap Finder →

Related topics in Medicine

Artificial Intelligence in Healthcare and Education
4,869 open questions
Dementia and Cognitive Impairment Research
3,297 open questions
Cancer Immunotherapy and Biomarkers
2,687 open questions
Liver Disease Diagnosis and Treatment
2,481 open questions
Substance Abuse Treatment and Outcomes
2,366 open questions
Sports Performance and Training
2,276 open questions
Mosquito-borne diseases and control
2,124 open questions
Parkinson's Disease Mechanisms and Treatments
2,117 open questions
Open questions raised by papers listed on this page include: (1) MITF-rearranged PEComas are rare, and their relationship to MITF-altered melanocytic tumors remains incompletely characterized (“Malignant MITF ‐Rearranged PEComa With Novel EEF1A1::MITF Fusion”, 2026); (2) The composition of a compact score varied with platform and preprocessing, so no fixed single-sample classifier is warranted (“A Reproducible Transcriptomic Program of Neurofibroma‐to‐Malignant Peripheral…”, 2026); (3) Prospective studies incorporating molecular stratification and adaptive radiotherapy are warranted (“Stereotactic radiosurgery for NF2-related schwannomatosis and…”, 2026); (4) The lack of detailed information about the AI4NEF platform, including its architecture, validation process, and clinical implementation (“Artificial intelligence in neurofibromatosis type I: diagnostic and therapeutic…”, 2026); (5) The underlying cause of bone impairment in these patients remains poorly understood, especially in children (“Neurofibromatosis type I (NF1) and bone involvement in a pediatric setting:…”, 2025). 271 gap statements have been mined from Neurofibromatosis and Schwannoma Cases papers in our 7.9M-paper local library, which holds 1,105 papers on the topic; the gaps come from whichever of those papers state one. They are mostly the research gaps the authors state and the papers' abstracts, plus future-work, limitations and challenges passages. The ones listed below are a selection still marked open; each names the study that raised it, with a DOI link where the paper has one, so you can read the original claim in context.

Tools for your next paper

Gaps & Literature SearchFind open questions in any field — 1,100,000+ open gaps mined from our own library.Pre-CheckIs your paper ready? Acceptance odds for top, mid and open/emerging journals, in seconds.Journal FinderA ranked shortlist of target journals from a 17,500-venue index.Duplicate Publication CheckerCheck for prior publication across 7 sources and our local library.Citation GeneratorFreeA DOI or title → APA, MLA, Vancouver, Chicago, BibTeX, RIS. No signup.Graphical Abstract MakerFreeTurn your findings into a colorblind-safe graphical abstract.

How Pre-Check worksHow AI Review works

Compare the category — Honest roundups of the AI research tools, ours listed alongside the alternatives.

Command palette

Jump anywhere, run any action.